iRhythm Holdings, Inc. (IRTC) Stock Price & Analysis

iRhythm Holdings, Inc. (IRTC) closed at USD 127.8 on Thursday, October 29, 2026, up 3.07% on the day. The US market is currently closed (after-hours); this is not a live price.

The prior close was USD 123.99; the Oct 29, 2026 session ranged USD 125.11–128.34 on volume of 550,248 shares. Market capitalization is $4.21B, with a 52-week range of USD 100.7–212 (NMS). Source: Nexqual, retrieved October 29, 2026 at 20:42 UTC.

Also available as compact Markdown for AI agents: nexqual.com/IRTC.md

Key facts (IRTC)

• Last four reported quarters (through Jun 30, 2026): revenue $825M, net income -$13.9M (-1.7% margin), free cash flow $39.0M (SEC filings).
• Insider open-market sales, last ~7 months: 15 Form 4 filings, $8.7M; 14 not under a Rule 10b5-1 plan ($8.1M); 1 by opportunistic insiders (1 outside 10b5-1 plans), 8 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Insider open-market purchases, last ~7 months: 1 Form 4 filing, $57K; 0 by opportunistic insiders, 0 by routine insiders.
• Analysts: Buy (mean 1.81 on a 1–5 scale) (16 analysts), mean target USD 171.33 (range 140–196).
• Total return with dividends: 1Y -30.6% vs S&P 500 +14.4%; 5Y +82.2% vs S&P 500 +79.1%.
• Next earnings: 2026-11-05, EPS estimate USD 0.05, revenue estimate $222M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (IRTC)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (IRTC)

P/S 5.1x · EV/Sales 5.3x · P/FCF 108.1x · P/B 22.6x · FCF yield 0.93% · Earnings yield -0.33% · Net debt $156M · EV $4.37B

Insider sales (SEC Form 4, open-market, last ~7 months) (IRTC)

1 of 15 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Insider purchases (SEC Form 4, open-market, last ~7 months) (IRTC)

1 purchase, $57K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.

Analysts (IRTC)

Consensus Buy (mean 1.81 on a 1–5 scale), 16 analysts; mean target USD 171.33 (low 140, high 196).

Rating changes, last 120 days:

Total return (dividends reinvested) (IRTC)

IRTC earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

IRTC recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

IRTC revenue by product line (quarter ended Jun 30, 2026)

As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).

IRTC suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Feb 19, 2026.

IRTC company outlook (results filed Aug 6, 2026)

• “For the full year 2026, iRhythm expects revenue between $880 million and $890 million and adjusted EBITDA margin between 13.0% and 14.0%, reflecting continued volume-led growth, gross margin expansion, and operating leverage while maintaining disciplined investment in innovation and market expansion.”

Quoted word-for-word from the SEC 8-K results press release.

IRTC analyst estimates and revisions

IRTC options: expected move

Options price a move of about ±11.2% (±$13.85) by Nov 20, 2026, which includes earnings on Nov 5, 2026. Over the last 8 reports the stock moved ±6.2% on average.

30-day implied volatility 51.6% vs 31.3% realized over the last 30 trading days. Put/call ratio (volume) 0. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 29, 2026 at 20:42 UTC)

Technical Analysis (IRTC)

Nexqual's technical model rates IRTC "BUY" based on 5 bullish and 3 bearish signals across 127 daily candles, as of October 29, 2026 at 20:42 UTC.

Analyst Ratings (IRTC)

Wall Street analysts rate IRTC "Buy" based on 16 analysts, with a mean price target of USD 171.33 (range USD 140–196), per Nexqual as of October 29, 2026 at 20:42 UTC.

Earnings (IRTC)

Recent Earnings History

Source: Nexqual, October 29, 2026 at 20:42 UTC.

Financials & Fundamentals (IRTC)

Source: Nexqual, October 29, 2026 at 20:42 UTC.

Financial Health Score (IRTC)

Nexqual rates iRhythm Holdings, Inc.'s overall financial health "Mixed" across five dimensions, as of October 29, 2026 at 20:42 UTC.

Ownership (IRTC)

Source: Nexqual, October 29, 2026 at 20:42 UTC.

Leadership (IRTC)

iRhythm Holdings, Inc. is led by Quentin S. Blackford, President, CEO & Director, per Nexqual as of October 29, 2026 at 20:42 UTC.

Major Backers & Investors (IRTC)

Notable institutional backers of iRhythm Holdings, Inc. include RTW Investments LP, Artisan Partners Limited Partnership, Millennium Management, according to Nexqual as of October 29, 2026 at 20:42 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 29, 2026 at 20:42 UTC.

From iRhythm Holdings, Inc.'s Latest SEC 10-K Filing (filed 2026-02-19)

Key Strengths & Strategy (as disclosed to the SEC)

• We believe our differentiated combination of patient-friendly, long-term wearable biosensors, proprietary FDA-cleared artificial intelligence algorithms, and integrated digital workflows enables physicians to obtain diagnostic certainty in a single test, improving patient care while reducing downstream healthcare utilization.
• We currently manufacture our iRhythm ACM Systems, including the Zio monitor System and Zio AT System, in our leased facility in Cypress, California.
• Our product portfolio includes patch-based solutions (utilized in our existing Zio monitor System, Zio AT System, and Zio XT System) and is planned to include the pending Zio MCT device for which we submitted an application to FDA in 2025.
• Most Class II devices, including Zio monitor, Zio AT, Zio XT, ZEUS and the Zio MCT device for which we are seeking marketing authorization, require 510(k) clearance from FDA in order to be marketed in the United States.

Partnerships

• In connection with the License Agreement, iRhythm Technologies also purchased an aggregate of $40.0 million of convertible promissory notes from BioIS (the "Convertible Notes"), of which $20.0 million ("Milestone Notes") were designated for satisfaction of our regulatory milestone payment obligations.

Legal & Regulatory Risks (Item 1A, quoted)

• The services and related devices we offer are highly regulated, and the regulatory environment in which we operate may change significantly and adversely in the future.
• Changes in applicable laws or regulations or the interpretation or enforcement policies of regulators governing our medical devices, IDTFs and iRhythm Services may constrain or require us to restructure our operations or adapt certain business strategies, which may harm our revenue and operating results.
• Our business could be negatively impacted by changes in the United States political environment.
• Any policy changes as a result of the current presidential administration and Congress could significantly affect our business as well as the markets in which we operate.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 20:42 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt